News | Endovascular Aortic Repair | May 23, 2017

New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair

Prospective, nonrandomized study evaluates endovascular repair of pararenal and thoracoabdominal aortic aneurysm using fenestrated-branched endografts based on supraceliac sealing zones

New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair

May 23, 2017 — Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and branched-graft devices, based on a report of prospectively studied patients with complex aortic aneurysm in the May edition of the Journal of Vascular Surgery.

Mayo Clinic researchers led by vascular surgeon Gustavo Oderich, M.D., reported no early mortality, need for permanent dialysis or open conversion, and two patients with paraplegia in their series of 127 patients (including 80 thoracoabdominal aneurysms).

At a follow-up averaging nine months, they had no ruptures or sac enlargement, but there was an 18 percent need for endovascular re-intervention.

Aortic aneurysm remains a significant cause of mortality and morbidity, particularly in aging patients. While most aneurysms involve the abdominal portion of the aorta (abdominal aortic aneurysm, or AAA), some develop aneurysmal degeneration more proximally involving the paravisceral and thoracic aorta. Repair of these aneurysms, traditionally performed by open surgical approaches, is considerably more complex with increased rates of death, dialysis and paraplegia following repair.

Endovascular therapies for more proximal aortic aneurysm are evolving and mainly involve the use of fenestrated and branched-graft designs. Complications specific to endovascular repair include loss of branch vessel patency (either intra-operative or in follow-up) and endoleak.  It is hoped that collaboration between the advanced vascular surgical teams performing these highly complex procedures and companies developing the products used for implantation will continue to drive success for patients with aortic aneurysm.

While these results are outstanding compared to open surgical treatment, Oderich noted that, “Follow-up is still too short to draw any conclusions about time-dependent outcomes, and it is likely that rates of reinterventions, vessel patency and endoleaks will be affected during longer follow-up.” 

For more information: www.jvascsurg.org


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now